Table 1.
Comparison of naive and experienced patients starting a rilpivirine-based combination antiretroviral therapy
| Naive (N=138, 27.7%)
|
Experienced (N=361, 72.3%)
|
p-value | |||
|---|---|---|---|---|---|
| N or mean or median | % or SD or IQR | N or mean or median | % or SD or IQR | ||
| TDF/FTC/RPV N (%) | 134 | 97.1 | 321 | 88.9 | |
| RPV/other N (%) | 4 | 2.9 | 40 | 11.1 | 0.004 |
| Gender N (%) | |||||
| Female | 35 | 25.4 | 104 | 28.8 | |
| Male | 103 | 74.6 | 257 | 71.2 | 0.44 |
| Age (years) | 38.1 | 10.3 | 45.5 | 9.9 | <0.0001 |
| Ethnicity N (%) | |||||
| Caucasian | 125 | 90.6 | 331 | 91.7 | |
| Other | 13 | 9.4 | 30 | 8.3 | 0.69 |
| HIV transmission category N (%) | |||||
| IVDU | 8 | 5.8 | 71 | 19.7 | |
| Homo/heterosexual | 124 | 89.9 | 266 | 73.7 | |
| Other or unknown | 6 | 4.3 | 24 | 6.6 | 0.0003 |
| CDC stage (1 missing) N (%) | |||||
| A | 107 | 77.5 | 203 | 56.2 | |
| B | 25 | 18.1 | 88 | 24.4 | |
| C | 6 | 4.4 | 70 | 19.4 | <0.0001 |
| CD4 count (cells/μL) N (%) | |||||
| <200 | 9 | 6.5 | 18 | 5.0 | |
| 200–349 | 46 | 33.3 | 37 | 10.2 | |
| ≥350 | 83 | 60.2 | 306 | 84.8 | <0.0001 |
| Undetectable HIV viral load N (%) | − | − | 70 | 19.4 | − |
| Lipodystrophy N (%) | 5 | 3.6 | 55 | 15.2 | 0.0004 |
| HCV antibody positive (2 missing) N (%) | 12 | 8.8 | 85 | 23.6 | 0.0002 |
| HCV-RNA positive (n=87) N (%) | 2 | 18.2 | 49 | 64.5 | 0.006 |
| Previous treatment including N (%): | |||||
| PI | − | − | 162 | 44.9 | |
| TDF/FTC/EFV | − | − | 135 | 37.4 | − |
| Other drugs | − | − | 64 | 17.7 | |
| Total cholesterol (md/dL)* | 165.0 | 35.4 | 188.4 | 42.1 | <0.0001 |
| HDL-C (md/dL)* | 40.8 | 13.2 | 48.5 | 16.7 | <0.0001 |
| Triglycerides (md/dL)** | 98.5 | 68.5–133.5 | 120 | 85–168 | <0.0001 |
| Blood glucose (md/dL)* | 87.8 | 20.4 | 91.6 | 21.2 | 0.07 |
| AST (U/L)** | 23 | 17–29 | 24 | 19–32 | 0.03 |
| ALT (mg/dL)** | 24 | 18–31 | 28 | 21–42 | 0.0001 |
| eGFR (mg/dL)** | 104 | 90–115 | 93 | 80–108 | <0.0001 |
Note: Data are expressed and mean ± standard deviation (SD)* or median and interquartile range (IQR)**.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; EFV, efavirenz; eGFR, estimated glomerular filtration rate; FTC, emtricitabine; HCV, hepatitis C virus; HDL-C, high-density lipoprotein cholesterol; IVDU, intravenous drug user; PI, protease inhibitor; RPV, rilpivirine; TDF, tenofovir.